Skip to main content

Type 2 diabetes and the risk of mortality among patients with prostate cancer



The aim of this study was to determine whether type 2 diabetes is associated with the incidence of prostate cancer mortality and all-cause mortality.


This study was conducted by linking four databases from the United Kingdom: the National Cancer Data Repository, the Clinical Practice Research Datalink, the Hospital Episodes Statistics database, and the Office for National Statistics database. The cohort consisted of men newly diagnosed with non-metastatic prostate cancer between 1 April 1998 and 31 December 2009, followed until 1 October 2012. Cox proportional hazard models were used to estimate adjusted hazard ratios with 95 % confidence intervals (CIs) of prostate cancer mortality and all-cause mortality comparing patients with to without type 2 diabetes. All models were adjusted for a number of potential confounders, which included excessive alcohol use, smoking, comorbidities, and prostate cancer-related variables.


The cohort consisted of 11,920 patients, which included 1,132 (9.5 %) with preexisting type 2 diabetes. During a mean follow-up of 4.7 (SD 3.0) years, there were 3,605 deaths (incidence rate: 6.4 %/year) including 1,792 from prostate cancer (incidence rate: 3.3 %/year). Type 2 diabetes was associated with a 23 % increased risk of prostate cancer mortality (HR 1.23, 95 % CI 1.04–1.46) and a 25 % increased risk in all-cause mortality (HR 1.25, 95 % CI 1.11–1.40).


The results of this large population-based study indicate that type 2 diabetes is associated with an increased risk of prostate cancer mortality and all-cause mortality, which may signal an association between hyperinsulinemia or other diabetes-associated metabolic derangements and cancer aggressivity.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2



Clinical Practice Research Datalink


Hospital Episodes Statistics


International Classification Of Diseases, 10th revision


Nonsteroidal anti-inflammatory drugs


Office of National Statistics


Office of Population Censuses and Surveys classification of interventions and procedures, 4th version


Prostate-specific antigen


United Kingdom


  1. Chowdhury TA (2010) Diabetes and cancer. QJM 103(12):905–915

    CAS  PubMed  Article  Google Scholar 

  2. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  3. Yeap BB, Alfonso H, Chubb SA et al (2012) Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 97(11):4030–4039

    CAS  PubMed  Article  Google Scholar 

  4. Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR (2005) History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 16(7):789–797

    CAS  PubMed  Article  Google Scholar 

  5. D’Amico AV, Braccioforte MH, Moran BJ, Chen MH (2010) Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 77(5):1329–1337

    PubMed  Article  Google Scholar 

  6. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76(5):1240–1244

    PubMed  Article  Google Scholar 

  7. Tseng CH (2011) Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men. Ann Med 43(2):142–150

    PubMed  Article  Google Scholar 

  8. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K (2012) The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 118(5):1353–1361

    PubMed  Article  Google Scholar 

  9. Shetti MB, Merrick GS, Butler WM et al (2012) The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Am J Clin Oncol 35(6):572–579

    PubMed  Article  Google Scholar 

  10. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL (2012) A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 35(1):113–118

    PubMed  Article  Google Scholar 

  11. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299–304

    PubMed  Article  Google Scholar 

  12. Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45(5):419–425

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  13. Read codes. United Kingdom National Health Service. Accessed 30 Dec 2013

  14. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302(6779):766–768

    CAS  PubMed  Article  Google Scholar 

  15. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21(3):299–304

    CAS  PubMed  Article  Google Scholar 

  16. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49(6):591–596

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  17. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686–689

    PubMed  Article  Google Scholar 

  18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69(1):4–14

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  19. Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81(3):515–526

    Article  Google Scholar 

  20. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P (2013) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 16(2):151–158 S1

    CAS  PubMed  Article  Google Scholar 

  21. Venkateswaran V, Haddad AQ, Fleshner NE et al (2007) Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99(23):1793–1800

    PubMed  Article  Google Scholar 

  22. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  23. Lubik AA, Gunter JH, Hendy SC et al (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71(17):5754–5764

    CAS  PubMed  Article  Google Scholar 

  24. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159–169

    CAS  PubMed  Google Scholar 

  25. Jones ME, Swerdlow AJ (1998) Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol 148(10):1012–1017

    CAS  PubMed  Article  Google Scholar 

  26. Schatzkin A, Slud E (1989) Competing risks bias arising from an omitted risk factor. Am J Epidemiol 129(4):850–856

    CAS  PubMed  Google Scholar 

  27. Albertsen PC, Walters S, Hanley JA (2000) A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 163(2):519–523

    CAS  PubMed  Article  Google Scholar 

Download references


L.B., S.S., and L.A. contributed to the study concept and design, to analysis and interpretation of data, to drafting of the manuscript, and to critical revision of the manuscript for important intellectual content. H.Y. and M.N.P. contributed to analysis and interpretation of data and to critical revision of the manuscript. L.A. supervised the study and is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This research was not funded. Laurent Azoulay is the recipient of a Chercheur-Boursier Award from the Fonds de la recherche en santé du Québec, and Samy Suissa is the recipient of the James McGill Chair.

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Laurent Azoulay.



See Tables 4, 5, 6, 7, and 8.

Table 4 Sensitivity analysis: type 2 diabetes and prostate cancer mortality censoring patients who developed type 2 diabetes in the non-diabetes group during follow-up
Table 5 Type 2 diabetes and the risk of non-prostate cancer mortality
Table 6 Effect measure modification by body mass index on the association between type 2 diabetes and mortality outcomes
Table 7 Effect measure modification by age on the association between type 2 diabetes and mortality
Table 8 Effect measure modification by Gleason score on the association between type 2 diabetes and mortality outcomes

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bensimon, L., Yin, H., Suissa, S. et al. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329–338 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Type 2 diabetes
  • Prostate cancer
  • Mortality
  • Hazard ratios